Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - fondaparinux sodium - injection, solution - 5.0 mg - fondaparinux sodium 5.0 mg/0.4 ml

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - fondaparinux sodium - injection, solution - 7.5 mg - fondaparinux sodium 7.5 mg/0.6 ml

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - fondaparinux sodium - injection - 2.5 mg/0.5 ml - fondaparinux sodium 2.5 mg/0.5 ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen notre dame de bondeville - fondaparinux (fondaparinux sodium) - solution for injection - 5mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen notre dame de bondeville - fondaparinux (fondaparinux sodium) - solution for injection - 5mg/ml

European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - fondaparinux sodium - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - antithrombotic agents - 1.5 mg/0.3 ml and 2.5 mg/0.5 ml, solution for injection:, prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery., prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1)., prevention of venous thromboembolic events (vte) in medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease., , 2.5 mg/0.5 ml, solution for injection:, treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) in patients for whom urgent (< 120 mins) invasive management (pci) is not indicated (see sections 4.4 and 5.1)., treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy., , 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml solution for injection:, treatment of acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.,

Singapore - English - HSA (Health Sciences Authority)

glorious dexa singapore pte. ltd. - fondaparinux sodium - injection, solution - fondaparinux sodium 2.5mg/0.5ml

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 5 mg / 1 ml - fondaparinux - fondaparinux - prevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture major knee surgery or hip replacement surgery. prevention of venous thromboembolic events (vte) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications such as patients undergoing abdominal cancer surgery. prevention of venous thromboembolic events (vte) in adults medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders and/or acute infectious or inflammatory disease. treatment of unstable angina or non-st segment elevation myocardial infarcton (ua/nstemi) in adults for whom urgent ( < 120 mins) invasive management (pci) is not indicated . treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 12.5 mg/ml - fondaparinux - fondaparinux - treatment of adults with acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

European Union - English - EMA (European Medicines Agency)

mylan ire healthcare limited - fondaparinux sodium - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - antithrombotic agents - 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionprevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.prevention of vte in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.prevention of vte in adult medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectiontreatment of unstable angina or non-st-segment-elevation myocardial infarction (ua/nstemi) in adult patients for whom urgent (< 120 mins) invasive management (pci) is not indicated.infarction (stemi) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectiontreatment of adults with acute deep-vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.